Invention Grant
- Patent Title: Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
-
Application No.: US16244851Application Date: 2019-01-10
-
Publication No.: US11149077B2Publication Date: 2021-10-19
- Inventor: Ray Camphausen , David Fabrizio , Martin C. Wright , Patrick Gage , John Mendlein
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee Address: US NJ Princeton
- Agency: Nelson Mullins Riley & Scarborough LLP
- Agent Jane E. Remillard, Esq.; Christopher L. Frank
- Main IPC: C07K14/78
- IPC: C07K14/78 ; C07K14/71 ; C07K16/28 ; A61K38/17 ; A61K38/39 ; A61K39/395 ; A61K47/10 ; A61K47/60 ; A61K47/64 ; A61K47/68 ; C12N15/10 ; C40B30/04 ; C40B40/08 ; A61K38/18 ; C07K14/00 ; C07K14/765 ; C07K14/79 ; C07K16/00 ; C07K14/47 ; A61K39/00 ; C07K19/00 ; C40B40/10
Abstract:
The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.
Public/Granted literature
- US20190202894A1 TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS FOR TYROSINE KINASES RECEPTORS, INCLUDING IGF-IR Public/Granted day:2019-07-04
Information query
